Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 109
Filtrar
1.
Unfallchirurg ; 118(6): 490-5, 2015 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-26013388

RESUMO

BACKGROUND: Popular trend sports are characterized by intensive and high speed performance. Due to the high energy mechanism in falls, typical injury distributions and patterns result. OBJECTIVES: In a retrospective study the injury patterns and frequencies in mountain bike athletes were analyzed and pathophysiological, diagnostic and therapeutic options in the treatment of high energy injuries to the carpal bones are shown. MATERIAL AND METHODS: Based on a retrospective survey over 2 successive years, active mountain bike athletes (World Cup Series) were interviewed using a standardized questionnaire. Injury patterns and frequencies were analyzed. The pathophysiology, diagnostics and therapy of high energy carpal injuries are discussed. RESULTS: In this study 107 World Cup mountain bike athletes were enrolled. Injuries of the extremities were found in more than 75% of athletes with a higher prevalence in the upper extremities (40.7%) than the lower extremities (34.84%), followed by injuries of the head and face (13.3%, of which 10.6% were traumatic brain injuries) and the trunk (10.6%). Fractures and dislocations of the hand and wrist were found in approximately half of the athletes (50.9%). CONCLUSION: In popular trend sports injuries of the extremities are common, especially of the carpal bones and ligaments. It is important to distinguish stable from destabilizing injuries in order to provide adequate therapeutic options.


Assuntos
Traumatismos em Atletas/epidemiologia , Ciclismo/lesões , Ciclismo/estatística & dados numéricos , Ossos do Carpo/lesões , Fraturas Ósseas/epidemiologia , Traumatismos em Atletas/terapia , Fraturas Ósseas/terapia , Traumatismos da Mão/epidemiologia , Humanos , Internacionalidade , Montanhismo/lesões , Montanhismo/estatística & dados numéricos , Traumatismo Múltiplo/epidemiologia , Traumatismo Múltiplo/terapia , Prevalência , Fatores de Risco , Traumatismos do Punho/epidemiologia
2.
Unfallchirurg ; 113(10): 796, 797-803, 2010 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-20842331

RESUMO

BACKGROUND: Following treatment of distal radius fractures poor functional results can still be found despite satisfactory radiological findings. This may be due to concomitant carpal lesions occurring together with these fractures. The aim of this prospective study was to analyze the clinical outcome depending on the type of fracture and concomitant carpal lesions. PATIENTS AND METHODS: A total of 66 patients with distal radius fractures treated over a 1-year period could be assessed. The functional results were compared with the uninjured contralateral side. The follow-up examination included patient history, physical and radiographic examination as well as the DASH (Disability of the arm, shoulder and hand) questionnaire and the modified Mayo wrist score. RESULTS: The average follow-up time was 12.7 months and the mean age of the examined patients was 53 years. The fracture classification according to AO (AO Working party for osteosynthesis questions) showed 32% type A, 10% type B and 58% type C fractures. In 55% a concomitant carpal lesion was found and 44% of the patients required surgical treatment. All fractures united without complications. In all cases X-rays showed no loss of reduction postoperatively. Overall grip strength and wrist motion was reduced to 81% compared to the uninjured side. Patients regained good function represented in a mean DASH score of 24.8 points and a Mayo score of 70.6 points. The number of complete intraarticular fractures (type C) was significantly higher in patients who needed surgical treatment for carpal lesions compared to the groups where concomitant carpal lesions did not require invasive treatment or those where no carpal lesions were found. However, due to the operative treatment a comparable functional result could be obtained in all groups independent of the injury severity. CONCLUSIONS: The results demonstrate, if a correct restoration and surgical stabilization technique is used, clinical outcome following fractures of the distal radius also depends on an optimized management of concomitant carpal lesions.


Assuntos
Ossos do Carpo/lesões , Ossos do Carpo/cirurgia , Fixação Interna de Fraturas/instrumentação , Traumatismo Múltiplo/cirurgia , Fraturas do Rádio/cirurgia , Traumatismos do Punho/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Ossos do Carpo/diagnóstico por imagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Traumatismo Múltiplo/diagnóstico por imagem , Radiografia , Fraturas do Rádio/diagnóstico por imagem , Resultado do Tratamento , Traumatismos do Punho/diagnóstico por imagem , Adulto Jovem
3.
Sportverletz Sportschaden ; 21(4): 180-4, 2007 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-18072077

RESUMO

This study investigated the incidence and frequency of injuries in mountainbike sports among competitive and recreational athletes. In a retrospective study design mountain-bike athletes were interviewed by means of a standardized questionnaire with regard to sports injuries and damages within the previous two years. The evaluation of time relative injury-rate was carried out under consideration of class and competition discipline. 75 % of the distributed questionnaires returned completed by 106 World-Cup (39 female symbol 67 male symbol, 23.1 y) and 134 recreational athletes (17 female symbol 117 male symbol, 27.4 y). Approximately 80 % of the World-Cup and about 50 % of the recreational athletes reported about at least one severe injury. World-Cup downhill athletes (1.08 injuries/ 1000 h) show a more than doubled time-related injury-rate in comparison with Cross-Country athletes (0.39 injuries/ 1000 h). Injuries of the lower (47 vs. 35 %) and upper extremity (40 vs. 41 %) show comparable prevalence for competitive and recreational cyclists. In the group of recreational athletes open wounds dominate, competitive athletes demonstrate a significant higher fracture-rate (p < 0.01). Within the World-Cup athletes head injuries stand out (n = 40). Although World-Cup participation does not result in essential injury-increase, the downhill discipline is characterized by a higher injury risk. Presumably in view of the performance orientation, there is a higher degree of risk readiness. Despite the riding performance and the obligatory safety equipment a remarkable number of bone and head injuries results.


Assuntos
Traumatismos em Atletas/etiologia , Ciclismo/lesões , Comportamento Competitivo , Recreação , Adulto , Altitude , Traumatismos em Atletas/epidemiologia , Causalidade , Estudos Transversais , Feminino , Alemanha , Humanos , Masculino , Estudos Retrospectivos , Fatores de Risco , Inquéritos e Questionários
5.
Leukemia ; 19(6): 984-9, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15830009

RESUMO

Gender-related aspects in chronic myeloid leukemia (CML) have not been studied well. We therefore analyzed 856 patients with Ph/BCR-ABL-positive CML from the German randomized CML-studies I (interferon alpha (IFN) vs hydroxyurea (HU) vs busulfan) and II (IFN+HU vs HU alone). The median observation time was 8.6 years. A total of 503 patients (59%) were male. Female patients were older (51 vs 46 years; P<0.0001), presented with lower hemoglobin (11.7 vs 12.5 g/dl; P<0.0001), higher platelet counts (459 vs 355 x 10(9)/l; P<0.0001), smaller spleen size (3 vs 4 cm below costal margin; P=0.0097), a lower rate of additional cytogenetic aberrations (9 vs 15%; P=0.018) and a less favorable risk profile (P=0.036). The transplantation rate was 14% for female (n=48) and 22% for male patients (n=113). Median survival was longer in female patients (58 vs 49 months; P=0.035) mainly attributable to better survival in the low- and intermediate-risk groups and, independent from risk groups, in the HU group. These results were confirmed by matched-pair analyses based on German population data (n=496, 59 vs 45 months; P=0.0006). This is the first analysis of gender aspects in CML using randomized trials. It demonstrates the relevance of analyses of gender differences in CML and in malignant disease at large.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/mortalidade , Caracteres Sexuais , Adulto , Distribuição por Idade , Idoso , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Bussulfano/administração & dosagem , Bussulfano/efeitos adversos , Causas de Morte , Feminino , Humanos , Hidroxiureia/administração & dosagem , Hidroxiureia/efeitos adversos , Interferon-alfa/administração & dosagem , Interferon-alfa/efeitos adversos , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Distribuição por Sexo , Análise de Sobrevida , Resultado do Tratamento
6.
Leukemia ; 19(6): 978-83, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15843821

RESUMO

The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m(2) q12h, days 1-3; mitoxantrone 10 mg/m(2), days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 x 10(9)/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Citarabina/administração & dosagem , Idarubicina/administração & dosagem , Leucemia Promielocítica Aguda/tratamento farmacológico , Mitoxantrona/administração & dosagem , Tretinoína/administração & dosagem , Adolescente , Adulto , Feminino , Humanos , Leucemia Promielocítica Aguda/genética , Leucemia Promielocítica Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Prognóstico , Proteínas Proto-Oncogênicas/genética , Receptores Proteína Tirosina Quinases/genética , Indução de Remissão , Tirosina Quinase 3 Semelhante a fms
7.
Leukemia ; 18(11): 1798-803, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15385923

RESUMO

The purpose of our study was (i) to evaluate the impact of all-trans retinoic acid (ATRA) given as adjunct to chemotherapy and (ii) to compare second consolidation vs maintenance therapy in elderly patients with acute myeloid leukemia (AML). A total of 242 patients aged >or=61 years (median, 66.6 years) with AML were randomly assigned to ATRA beginning on day +3 after the initiation of chemotherapy (ATRA-arm, n=122) or no ATRA (standard-arm, n=120) in combination with induction and first consolidation therapy. A total of 61 patients in complete remission (CR) were randomly assigned to second intense consolidation (n=31) or 1-year oral maintenance therapy (n=30). After induction therapy the intention-to-treat analysis revealed a significant difference in CR rates between the ATRA- and the standard-arm (52 vs 39%; P=0.05). Event-free (EFS) and overall survival (OS) were significantly better in the ATRA-compared to the standard-arm (P=0.03 and 0.01, respectively). OS after second randomization was significantly better for patients assigned to intensive consolidation therapy (P<0.001). The multivariate model for survival revealed lactate dehydrogenase, cytogenetic risk group, age, and first and second randomization as prognostic variables. In conclusion, the addition of ATRA to induction and consolidation therapy may improve CR rate, EFS and OS in elderly patients with AML.


Assuntos
Anemia Refratária com Excesso de Blastos/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide/terapia , Doença Aguda , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Citarabina/administração & dosagem , Etoposídeo/administração & dosagem , Humanos , Idarubicina/administração & dosagem , Pessoa de Meia-Idade , Prognóstico , Indução de Remissão , Taxa de Sobrevida , Transplante Homólogo , Tretinoína/administração & dosagem
8.
Br J Haematol ; 126(2): 252-4, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15238147

RESUMO

The NB1 glycoprotein (CD177, HNA-2a antigen) is exclusively expressed on human neutrophils. As the clinical significance of CD177 expression is unknown, we investigated its expression in healthy individuals before and after stimulation with granulocyte colony-stimulating factor (G-CSF), in patients with rheumatoid arthritis, viral hepatitis, severe bacterial infections and polycythaemia vera. Expression was quantitatively determined by flow cytometry and by real time polymerase chain reaction. Only G-CSF-stimulated individuals and patients with severe bacterial infections and polycythaemia showed a significantly (P < 0.001) increased CD177 expression compared with healthy individuals, indicating that neutrophil CD177 expression can increase significantly in certain clinical conditions.


Assuntos
Infecções Bacterianas/imunologia , Isoantígenos/imunologia , Glicoproteínas de Membrana/imunologia , Neutrófilos/imunologia , Policitemia Vera/imunologia , Adulto , Artrite Reumatoide/imunologia , Estudos de Casos e Controles , Feminino , Citometria de Fluxo , Proteínas Ligadas por GPI , Fator Estimulador de Colônias de Granulócitos/farmacologia , Hepatite Viral Humana/imunologia , Humanos , Masculino , Receptores de Superfície Celular , Reação em Cadeia da Polimerase Via Transcriptase Reversa
9.
Leukemia ; 17(9): 1820-6, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12970782

RESUMO

Chronic myeloid leukemia (CML) in older patients has not been studied well. To assess the long-term outcome of older patients with Philadelphia- and/or BCR-ABL-positive CML, 199 patients aged >/=60 years representing 23% of 856 patients enrolled in the German randomized CML-studies I (interferon alpha (IFN) vs hydroxyurea (HU) vs busulfan (BU) and II (IFN+HU vs HU alone) were analyzed after a median observation time of 7 years. In all, 45 patients were treated with Bu, 63 with HU, and 91 with IFN. The 5-year survival was 38% in patients >/=60 years and 47% in patients <60 years (P<0.001). Whereas 5-year survival in chemotherapy-treated older patients was inferior to that in younger patients (33 vs 46%, P=0.006 for HU and 29 vs 38%, P=0.042 for Bu), no significant survival difference could be verified in IFN-treated patients (46 vs 53%, P=0.077). Calculation of age-adjusted, relative survival confirmed these results. Adverse effects of IFN were similar in both age groups, but IFN dosage to achieve treatment goals was lower in older patients. We conclude that the course of CML is not different in the elderly. They require lower IFN doses, achieve the same hematologic and cytogenetic response rates and the same survival advantage at comparable toxicity.


Assuntos
Antineoplásicos/uso terapêutico , Interferon-alfa/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Proteínas Tirosina Quinases/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bussulfano/uso terapêutico , Criança , Feminino , Seguimentos , Proteínas de Fusão bcr-abl , Humanos , Hidroxiureia/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/mortalidade , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Risco , Taxa de Sobrevida , Resultado do Tratamento
10.
Leukemia ; 17(8): 1521-8, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12886238

RESUMO

The objective of the AML HD93 treatment trial was to evaluate the outcome in young adults with acute myeloid leukemia (AML) after postremission therapy was stratified according to cytogenetically defined risk. The rationales for the study design were based (i) on previous favorable results with high-dose cytarabine in AML with t(8;21), inv/t(16q22) and in AML with normal karyotype, and ii) on encouraging results obtained in several phase II trials using autologous stem cell transplantation (SCT). Between July 1993 and January 1998, 223 eligible patients, 16-60 years of age with newly diagnosed AML other than French-American-British type M3/M3v, were entered into the trial. Risk groups were defined as follows: low risk: t(8;21) or inv/t(16q22); intermediate risk: normal karyotype; high risk: all other chromosomal abnormalities. Following intensive double induction therapy with idarubicin, cytarabine and etoposide, all patients in complete remission (CR) received a first consolidation therapy with high-dose cytarabine and mitoxantrone (HAM). A second consolidation therapy was stratified according to the risk group: low risk: HAM; intermediate risk: related allogeneic SCT or sequential HAM; high risk: related allogeneic or autologous SCT. Double induction therapy resulted in a high CR rate of 74.5%, and 90% of the responding patients were eligible for consolidation therapy. Survival for all 223 trial entrants was 40%, and for the 166 patients who entered CR, disease-free (DFS) and overall survival were 40 and 51% after 5 years, respectively. Within the low-, intermediate- and high-risk groups, DFS and survival after 5 years were 62.5 and 87, 40 and 49 and 17 and 26% respectively, without advantage for allogeneic transplantation in the intermediate- and high-risk groups. Postremission therapy-related mortality was 0, 7 and 14%, respectively. This study demonstrates the feasibility of cytogenetically defined risk-adapted consolidation therapy. The overall trial results are at least equivalent to those of published trials supporting the risk-adapted treatment strategy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide/terapia , Doença Aguda , Adolescente , Adulto , Algoritmos , Citarabina/uso terapêutico , Análise Citogenética , Feminino , Humanos , Leucemia Mieloide/diagnóstico , Leucemia Mieloide/mortalidade , Masculino , Pessoa de Meia-Idade , Mitoxantrona/uso terapêutico , Indução de Remissão/métodos , Medição de Risco , Transplante de Células-Tronco/métodos , Transplante de Células-Tronco/mortalidade , Análise de Sobrevida
11.
Leukemia ; 17(8): 1529-37, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12886239

RESUMO

The optimum treatment conditions of interferon (IFN) alpha therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a randomized trial to compare the combination of IFN and HU vs HU monotherapy (CML-study II). From February 1991 to December 1994, 376 patients with newly diagnosed CML in chronic phase were randomized. In all, 340 patients were Ph/BCR-ABL positive and evaluable. Randomization was unbalanced 1:2 in favor of the combination therapy, since study conditions were identical to the previous CML-study I and it had been planned in advance to add the HU patients of study I (n=194) to the HU control group. Therefore, a total of 534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU). Analyses were according to intention-to-treat. Median observation time of nontransplanted living patients was 7.6 years (7.9 years for IFN/HU and 7.3 years for HU). The risk profile (new CML score) was available for 532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk. Complete hematologic response rates were higher in IFN/HU-treated patients (59 vs 32%). Of 169 evaluable IFN/HU-treated patients (75%), 104 patients (62%) achieved a cytogenetic response that was complete in 12% (n=21), major in 14% (n=24), and at least minimal in 35% (n=59). Of the 534 patients, 105 (20%) underwent allogeneic stem cell transplantation in first chronic phase. In the low-risk group, 65 of 200 patients were transplanted (33%), 30 (13%) in the intermediate-risk group, and nine (10%) in the high-risk group. Duration of chronic phase was 55 months for IFN/HU and 41 months for HU (P<0.0001). Median survival was 64 months for IFN/HU and 53 months for HU-treated patients (P=0.0063). We conclude that IFN in combination with HU achieves a significant long-term survival advantage over HU monotherapy. In view of the data of CML-study I, these results suggest that IFN/HU is also superior to IFN alone. HU should be combined with IFN in IFN-based therapies and for comparisons with new therapies.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Hidroxiureia/administração & dosagem , Interferon-alfa/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/mortalidade , Adolescente , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Causas de Morte , Criança , Análise Citogenética , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Hidroxiureia/toxicidade , Masculino , Pessoa de Meia-Idade , Indução de Remissão/métodos , Medição de Risco , Análise de Sobrevida , Transplante Homólogo
12.
Cancer Immunol Immunother ; 49(11): 573-86, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11225988

RESUMO

Immunosuppressive features of tumour cells are a major obstacle for immunotherapy of cancer. We recently noted that RENCA cells effectively interfere with the in vivo activation of RENCA-specific T cells. To unravel the underlying mechanism, we evaluated the influence of RENCA cells on a mixed-lymphocyte/ tumour reaction as well as an allogeneic mixed-lymphocyte reaction. We observed that RENCA cells were not directly immunosuppressive. Instead, they initiated deviation of an immune response in at least two independent directions: (i) expansion of a population of NK1.1+/CD3+ cells, which was accompanied by elimination of mainly CD4+ lymphocytes, and (ii) production of a leukocyte-derived inhibitory factor. Expression of the costimulatory molecule B7.1 by RENCA cells prevented induction of anergy, while expression of MHC class II molecules prevented expansion of NK1.1+ cells, which was accompanied by a significant decrease in cell death. Hence, an unimpaired response was observed only when RENCA cells expressed B7.1 plus MHC class II molecules. Thus, even if a tumour itself is not immunosuppressive, it can induce a strong deviation of the immune response. It is concluded that the first contact between elements of the immune system and the tumour cell can confer a severe bias on immunoregulatory circuits.


Assuntos
Carcinoma de Células Renais/imunologia , Tolerância Imunológica , Neoplasias Renais/imunologia , Evasão Tumoral , Animais , Antígenos/imunologia , Antígenos Ly , Antígenos de Superfície , Apoptose , Antígeno B7-1/imunologia , Complexo CD3/imunologia , Linfócitos T CD4-Positivos/imunologia , Células Clonais , Citocinas/biossíntese , Proteína Ligante Fas , Antígenos de Histocompatibilidade Classe II/imunologia , Isoantígenos/imunologia , Lectinas Tipo C , Ativação Linfocitária , Teste de Cultura Mista de Linfócitos , Glicoproteínas de Membrana/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Subfamília B de Receptores Semelhantes a Lectina de Células NK , Proteínas/imunologia , Fatores Supressores Imunológicos/biossíntese , Células Tumorais Cultivadas
13.
Med Klin (Munich) ; 95(9): 517-22, 2000 Sep 15.
Artigo em Alemão | MEDLINE | ID: mdl-11028168

RESUMO

HISTORY: A 65-year-old woman had suffered from relapsing ventricular tachycardias (VT) since 1996. FINDINGS: Physical examination was normal. An arrhythmogenic substrate was found in the right ventricular outflow tract by electrophysiological examination. Nuclear magnetic resonance imaging (MRI) showed an infiltration of the right heart. Myocardial biopsy revealed a high-grade centroblastic non Hodgkin lymphoma. The patient was now transferred to our hospital for further treatment. Lactate dehydrogenase was elevated (2,030 U/l). Echocardiography showed a thickened and more reflecting right ventricular myocardium. Bone marrow aspiration and MRI/computed tomography of abdomen and thorax excluded a generalized stage. Ventricular tachycardias were caused by a primary cardiac lymphoma. TREATMENT AND COURSE: Combined radio-chemotherapy succeeded in complete remission. High-frequency ablation and amiodarone failed. Although MRI showed no more vital lymphoma after the combined radio-chemotherapy the patient suffered from spontaneous and symptomatic relapses of VT. Therefore this patient with primary cardiac lymphoma was the first in literature to get a defibrillator (ICD). The incidence of VT decreased and up to now the patient showed no relapse of the non Hodgkin lymphoma (follow-up 23 months).


Assuntos
Neoplasias Cardíacas/diagnóstico , Linfoma não Hodgkin/diagnóstico , Miocárdio/patologia , Taquicardia/terapia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biópsia , Desfibriladores Implantáveis , Diagnóstico Diferencial , Eletrocardiografia , Feminino , Neoplasias Cardíacas/complicações , Neoplasias Cardíacas/tratamento farmacológico , Neoplasias Cardíacas/patologia , Humanos , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/patologia , Taquicardia/etiologia , Resultado do Tratamento
15.
Dtsch Med Wochenschr ; 125(6): 147-50, 2000 Feb 11.
Artigo em Alemão | MEDLINE | ID: mdl-10700878

RESUMO

HISTORY AND ADMISSION FINDINGS: A 24-year-old man with thrombocytopenia was referred for surgical resection of a bleeding polyp of the sigmoid. Examination showed a small haematoma and petechiae on both lower legs. The patient reported that several male family members also had a thrombocytopenic bleeding tendency. INVESTIGATIONS: Laboratory tests revealed thrombocytopenia (4000 platelets/ml, with small platelets: mean platelet volume [MPV] 5.6 ml). Serum immunoglobulins were normal. A mutation in the Wiskott-Aldrich (W-A) protein gene (intron 7 + 5 G-->A) was demonstrated both in the patient and his 26-year-old brother. DIAGNOSIS, TREATMENT AND COURSE: The diagnosis of W-A syndrome was made and, with perioperative administration of platelets, the polyp was resected without complication. CONCLUSION: Most patients with the W-A syndrome die by the time they are aged 10 years, unless appropriate treatment is given. This patient and his brother had a mutation of the W-A protein gene that unusually was in an intron rather than in an exon. Structurally normal W-A proteins were still being formed. This may explain the mild course and late onset of the disease.


Assuntos
Síndrome de Wiskott-Aldrich/diagnóstico , Adulto , Biópsia por Agulha , Medula Óssea/patologia , Terapia Combinada , Ligação Genética , Humanos , Masculino , Mutação , Contagem de Plaquetas , Proteínas/genética , Síndrome de Wiskott-Aldrich/genética , Síndrome de Wiskott-Aldrich/patologia , Síndrome de Wiskott-Aldrich/terapia , Proteína da Síndrome de Wiskott-Aldrich , Cromossomo X/genética
16.
J Lab Clin Med ; 135(3): 247-55, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10711863

RESUMO

Flow cytometry can detect platelet activation (CD62p), aggregate formation, microparticle formation, and glycoprotein IIb/IIIa (GP IIb/IIIa) receptor occupancy in one sample at the level of single particles. We studied the effect of GP IIb/IIIa inhibitors on platelet activation with flow cytometry in vitro. Citrated whole blood was incubated with increasing concentrations of three different GP IIb/IIIa inhibitors (c7E3, DMP728, XJ757), then thrombin or adenosine diphosphate (ADP) was added, and after 1 minute the sample was fixed. Samples with thrombin but without c7E3 had a decrease in platelet count, from a mean of 260,000 platelets/microl to 56,000 platelets/microL, and aggregates increased. Samples with concentrations of c7E3 that resulted in 80% or more receptor blockade had no decrease in platelet count, and no aggregates were formed, but the number of CD62p-positive single platelets increased from 1200 to 7400 platelets/microL. The two other inhibitors (DMP 725, XJ757) or ADP instead of thrombin gave similar results. Microparticle formation did not change with platelet activation in the presence of a GP IIb/IIIa inhibitor. With small inhibitor doses resulting in <80% receptor blockade, the number of aggregates did not change or was even higher than that in samples without inhibitor. GP IIb/IIIa inhibitors do prevent aggregate formation but they do not prevent activation of platelets. With GP IIb/IIIa inhibition, more activated single platelets remain in the blood. One may expect an increasing number of circulating, activated platelets with the use of GP IIb/IIIa inhibitors.


Assuntos
Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Selectina-P/metabolismo , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Anticorpos Monoclonais/farmacologia , Plaquetas/imunologia , Citometria de Fluxo , Humanos , Técnicas In Vitro , Mesilatos/farmacologia , Peptídeos Cíclicos/farmacologia , Ativação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Contagem de Plaquetas , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/imunologia
17.
Blood ; 94(11): 3668-77, 1999 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-10572078

RESUMO

The influence of interferon-alpha (IFN) pretreatment on the outcome after allogeneic bone marrow transplantation (BMT) in chronic myelogenous leukemia (CML) is controversial. One goal of the German randomized CML Studies I and II, which compare IFN +/- chemotherapy versus chemotherapy alone, was the analysis of whether treatment with IFN as compared to chemotherapy had an influence on the outcome after BMT. One hundred ninety-seven (23%) of 856 Ph/bcr-abl-positive CML patients were transplanted. One hundred fifty-two patients transplanted in first chronic phase were analyzed: 86 had received IFN, 46 hydroxyurea, and 20 busulfan. Forty-eight patients (32%) had received transplants from unrelated donors. Median observation time after BMT was 4.7 (0.7 to 13.5) years. IFN and chemotherapy cohorts were compared with regard to transplantation risks, duration of treatments, interval from discontinuation of pretransplant treatment to BMT, conditioning therapy, graft-versus-host disease prophylaxis and risk profiles at diagnosis and transplantation, and IFN cohorts also with regard to performance and resistance to IFN. Outcome of patients receiving related or unrelated transplants pretreated with IFN, hydroxyurea, or busulfan was not significantly different. Five-year survival after transplantation was 58% for all patients (57% for IFN, 60% for hydroxyurea and busulfan patients). The outcome within the IFN group was not different by duration of prior IFN therapy more or less than 5 months, 1 year, or 2 years. In contrast, a different impact was observed in IFN-pretreated patients depending on the time of discontinuation of IFN before transplantation. Five-year survival was 46% for the 50 patients who received IFN within the last 90 days before BMT and 71% for the 36 patients who did not (P =.0057). Total IFN dosage had no impact on survival after BMT. We conclude that outcome after BMT is not compromised by pretreatment with IFN if it is discontinued at least 3 months before transplantation. Clear candidates for early transplantation should not be pretreated with IFN.


Assuntos
Transplante de Medula Óssea , Fatores Imunológicos/administração & dosagem , Interferon-alfa/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transplante Homólogo , Resultado do Tratamento
18.
J Lab Clin Med ; 131(6): 507-17, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9626986

RESUMO

With fluorescent beads it has become possible to determine absolute numbers of cells in a given sample instead of relative percentages on a standard flow cytometer. This study assesses the ability to count platelets, microparticles, and aggregates with a flow cytometer. Whole blood was stimulated with 0.1 U thrombin per milliliter. Platelet and microparticle counts decreased, while the number of aggregates increased. Unactivated whole blood was diluted with buffer and showed a corresponding decrease in the concentration of platelets, microparticles, and aggregates. The platelet count on the flow cytometer was always in good correlation with counts on an automated blood analyzer. Only the cytometer, and not the automated analyzer, was able to detect and count microparticles and aggregates. In highly diluted samples of unactivated whole blood there was a spurious relative increase in CD62p-positive platelets because of a surplus of anti-CD62p antibodies and a relative increase in microparticles. Flow cytometry is a valuable method for counting platelets, aggregates, and microparticles in unstimulated and activated blood samples. If the platelet count changes and drops to less than 50% of the count for which the amount of antibody and the cytometer settings have initially been adjusted, care has to be taken to avoid misinterpretation.


Assuntos
Agregação Plaquetária/fisiologia , Contagem de Plaquetas/métodos , Anticorpos Monoclonais/imunologia , Citometria de Fluxo/métodos , Fluorescência , Humanos , Selectina-P/imunologia , Ativação Plaquetária/fisiologia , Trombina/farmacologia
19.
Haemostasis ; 28(6): 277-88, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-10461010

RESUMO

Standard flow cytometers provide relative numbers of activated platelets, microparticles, and platelet aggregates. With fluorescent beads it is now possible to determine absolute numbers. Whole blood and platelet-rich plasma were incubated with agonists (ADP, collagen, thrombin). CD62p expression, microparticle and platelet aggregate formation were measured. Flow-Count Fluorospheres((R)) were added to calculate absolute concentrations. After activation there was an increase in the percentage of CD62p-positive platelets. However, the total number of platelets decreased and therefore the absolute number of CD62p-positive platelets did not increase but decreased. The number of CD62p-positive platelets decreased not as much as the number of CD62p-negative platelets, which explains why the relative percentage of CD62p-positive platelets increased. A similar increase in percent and decrease in absolute counts was found for microparticles. Platelet aggregates increased both in relative and absolute numbers. These results suggest that the detection of activated platelets by flow cytometry has to be complemented by the determination of the absolute concentrations to avoid misinterpretation.


Assuntos
Plaquetas/fisiologia , Ativação Plaquetária , Plaquetas/patologia , Citometria de Fluxo , Hemostáticos/farmacologia , Humanos , Selectina-P , Agregação Plaquetária , Trombina/farmacologia
20.
Haemostasis ; 28(1): 37-44, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9885369

RESUMO

Platelets express the receptor for thrombopoietin. It is possible that thrombopoietin modulates platelet reactivity. We examined the effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet activation in vitro using flow cytometry. We compared samples from healthy individuals and from patients with various hematologic diseases (AML, myeloma, postchemotherapy). Citrated whole blood was incubated with PEG-rHuMGDF (10 or 100 ng/ml), then a mild stimulus was added (0.1 U thrombin/ml). Blood from healthy individuals showed a significantly higher degree of platelet activation (CD62p expression), microparticle generation, and aggregate formation after incubation with PEG-rHuMGDF+thrombin versus thrombin alone (p < 0.05). However, this difference could not be shown for platelets from patients with thrombocytopenia or other hematologic diseases. The use of PEG-rHuMGDF should be safe and not cause an additional risk of thromboocclusive disease in these patients.


Assuntos
Doenças Hematológicas/sangue , Ativação Plaquetária/efeitos dos fármacos , Polietilenoglicóis/farmacologia , Trombopoetina/farmacologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Leucemia Mieloide Aguda/fisiopatologia , Masculino , Megacariócitos/efeitos dos fármacos , Pessoa de Meia-Idade , Agregação Plaquetária/efeitos dos fármacos , Contagem de Plaquetas , Proteínas Recombinantes/farmacologia , Cloreto de Sódio/farmacologia , Trombina/farmacologia , Trombocitopenia/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA